8-Cyclopentyl-1,3-dipropyl-xanthine

DPCPX

1,3-Dipropyl(8-cyclopentyl)xanthine

Catálogo Nº Apresentação Preço (R$) Comprar / Observação
N-1077 200 μl (1 mM) Sob demanda Adicionar ao Carrinho
Structural formula of 8-Cyclopentyl-1,3-dipropyl-xanthine (DPCPX, 1,3-Dipropyl(8-cyclopentyl)xanthine)
Structural formula of 8-Cyclopentyl-1,3-dipropyl-xanthine

For research use only!

Envio: shipped at ambient temperature

Condições de armazenamento: store at 4 °C
Short term exposure (up to 1 week cumulative) to ambient temperature possible.

Validade: 24 months after date of delivery

Fórmula molecular: C16H24N4O2

Peso molecular: 304.39 g/mol

CAS#: 102146-07-6

Pureza: ≥ 95 % (HPLC)

Forma: solution in DMSO

Concentração: 1 mM

Formulários:
Binding studies, physiological studies on cell cultures or tissues and in animal experiments.
Compound has highest activity to nucleoside receptor type A1. Functionally, DPCPX can act as antagonist for A1, A2A and A3[1].

Usage: Dissolve stock solution with aqueous physiological buffer recommended for displacement studies, biochemical signal transduction studies or animal experiments.
To avoid biological effects of DMSO dilute the stock solutions with aqueous buffers to a content of DMSO below 1 %.

Please note: Stable in acidic and neutral buffer solutions for one day

Referências selecionadas:
[1] Goncalves et al. (2008) Presynaptic adenosine and P2Y receptors. Handbook of Experimental Pharmacology 184:339.
Sirci et al. (2012) Ligand-, structure- and pharmacophore-based molecular fingerprints: a case study on adenosine A1, A2A, A2B, and A3 receptor antagonists. J. Comput. Aided Mol. Des. 26:1247.
Shenone et al. (2010) A1 Receptors Ligands: Past, present and future trends. Cur. Topics in Medicin. Chem. 10:878.
Ishiwata et al. (2007) PET tracers for mapping adenosine receptors as probes for diagnosis of CNS disorders. Central Nervous System Agents in Medicinal Chemistry 7:57.
Wittendorp et al. (2004) The mouse brain adenosine A1 receptor: functional expression and pharmacology. Europ. J. Pharmacol. 487:73.
Soudijn et al. (2002) Allosteric modulation of G protein-coupled receptors. Current Opinion in Drug Discovery & Development 5 (5):749.
Hess (2001) Recent advantages in adenosine receptor antagonist research. Expert Opin. Ther. Patents 11 (10):1533.
Merighi et al. (2001) Pharmacological and biochemical characterization of adenosine receptors in the human malignant melanoma A375 cell line. Brit. J. Pharmacol. 134:1215.
Klotz et al. (1998) Comparative pharmacology of human adenosine receptor subtypes – characterization of stable transfected receptors in CHO cell. Naunyn-Schmiedeberg's Arch. Pharmacol. 357:1.